Parecoxib provides a unique key which can not only enhance resveratrol in reducing cancer cell viability, but also enhance apoptosis via the suppression of Akt activation and TXNDC5 expression, upregulating the JNK and p38 MAPK signaling pathway, as well as increasing p53 and Bax expression and decreasing Bcl-2 expression in colorectal cancer, thereby enlarging cleaved PARP and enhancing apoptosis (Figure 9). The gene discussed is TXNDC5; the disease is colorectal cancer.